Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer
Autore:
Preti, RA; Lazarus, HM; Winter, J; Stadtmauer, EA; Nadasi, S; McMannis, J; Karandish, S; Jennis, A; Goldberg, SL; Pecora, AL;
Indirizzi:
Progenitor Cell Therapy LLC, Cellular Therapy Lab, Hackensack, NJ 07601 USA Progenitor Cell Therapy LLC Hackensack NJ USA 07601 kensack, NJ 07601 USA Hackensack Univ, Med Ctr, Hackensack, NJ USA Hackensack Univ Hackensack NJ USA sack Univ, Med Ctr, Hackensack, NJ USA Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA Case Western Reserve Univ Cleveland OH USA 44106 Cleveland, OH 44106 USA Northwestern Univ Hosp, Chicago, IL USA Northwestern Univ Hosp Chicago ILUSA western Univ Hosp, Chicago, IL USA Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA Univ Penn Philadelphia PAUSA 19104 Ctr Canc, Philadelphia, PA 19104 USA Nexell Therapeut, Irvine, CA USA Nexell Therapeut Irvine CA USANexell Therapeut, Irvine, CA USA
Titolo Testata:
CYTOTHERAPY
fascicolo: 2, volume: 3, anno: 2001,
pagine: 85 - 95
SICI:
1465-3249(2001)3:2<85:TCDOPB>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
AUTOLOGOUS BONE-MARROW; POLYMERASE CHAIN-REACTION; COLONY-STIMULATING FACTOR; HIGH-DOSE CHEMOTHERAPY; NON-HODGKINS-LYMPHOMA; HEMATOPOIETIC STEM; PHASE-II; TRANSPLANTATION; RELAPSE; CYCLOPHOSPHAMIDE;
Keywords:
CD34 selection; positive selection; negative selection; immunomagnetic beads; Isolex; metastatic breast cancer transplantation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Preti, RA Progenitor Cell Therapy LLC, Cellular Therapy Lab, 20 Prospect Ave,Suite 400, Hackensack, NJ 07601 USA Progenitor Cell Therapy LLC 20 Prospect Ave,Suite 400 Hackensack NJ USA 07601
Citazione:
R.A. Preti et al., "Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer", CYTOTHERAPY, 3(2), 2001, pp. 85-95

Abstract

BackgroundThe clinical relevance of tumor cell purging of hematopoietic progenitor cell grafts has yet to be conclusively determined. Therefore, in addition tothe demonstration that a method for graft purification is capable of removing an adequate number of tumor cells, it is critical that the procedure has as benign an impact upon the hematopoietic repopulating potential of the graft as possible. We evaluated tumor cell depletion, recovery of CD34(+) cells and post transplant engraftment kinetics as accepted measures of the effectiveness of an immunomagnetic bead (positive and positive/negative) purging methodology. MethodsThe patients received either positive selection (CD34 selection alone) or a combination of positive and negative (CD34 selection followed by breast cancer cell depletion) using the Isolex 300 (automated and semi-automated) devices. Immunocytochemistry was used to determine the degree of breast cancer cell contamination before and after the selection procedures to determine the efficacy of the procedure. CD34 enumeration was employed to evaluate the recovery and purity of the CD34-selected cellular products and engraftment indices (days to absolute neutrophil count (ANC) recovery and platelet count (Plt) recovery and transfusion requirements) were evaluated to determine the safety of the procedure. ResultsA total of 130 aphereses was performed on 101 patients. Ten pairs of collections were polled before selection to increase the likelihood of achievingCD34 dose goals after selection. In all, 100 positive selections and 20 positive/negative selections were performed. Of the 10 (10.4%) ICC-positive preselection samples, 2 products showed persistent contamination after processing. The majority of patients (85.4%) required one selection procedure toachieve an adequate CD34(+) selected cell dose. Median CD34(+) cell recovery was > 50% for positive selection procedures and > 60% for the positive/negative procedures. The dose of CD34(+) cells infused ranged from 0.76 x 10(6) CD34(+) cells/kg to 27.7 x 10(6) CD34(+) cells/kg. There were no significant delays in neutrophil or platelet recovery or infections between any of the treatment groups. DiscussionCD34 selection alone or in combination with negative selection can result in a significant reduction of contaminating tumor cells in the peripheral blood progenitor cell autograft. Although there was one engraftment failure with the CD34-positive selected cells, transplantation of the selected products after high-dose chemotherapy for metastic breast cancer did not resultin a clinically significant delay in the hematopoietic reconstitutive capacity of the autografts.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 22:59:59